[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100225001":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":18,"collaborators":10,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":25,"acronym":10,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":10,"maxAge":10,"enrollmentInfo":28,"targetDuration":10,"studyType":31,"phases":10,"briefSummary":32,"conditions":33,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":10,"leadSponsor":42,"locationsCount":10},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Metalyse",null,"weight-adjusted dose",[13],"Drug: Metalyse",[15],{"type":16,"name":9,"description":10,"armGroupLabels":17,"otherNames":10},"DRUG",[9],{"type":19,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100225001","post-marketing-surveillance-to-monitor-the-safety-and-efficacy-of-metalyse-in-korean-patients-with-acute-myocardial-infarction-100225001",false,"NCT02206646","Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction","Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® (Tenecteplase) in Korean Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* none\n\nExclusion Criteria:\n\n* none","ALL",{"count":29,"type":30},987,"ACTUAL","OBSERVATIONAL","To monitor the safety of Metalyse® in clinical practice in patients with acute myocardial infarction over a period of 6 years as required by Korean authorities, with the following observations:\n\n1. Unexpected adverse drug reactions\n2. Frequency and nature of adverse events (AEs)\n3. Factors on the safety and efficacy profile of the Metalyse® Injection. Efficacy of Metalyse® was also assessed.",[34],"Myocardial Infarction","COMPLETED","2014-07-31",{"date":38,"type":39},"2014-08-01","ESTIMATED",{"date":41,"type":10},"2003-02",{"name":5,"class":6}]